Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mu
Go back to Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mu| Textainer Group Holdings limited (NASDAQ: GH) | Delayed: 130.83 +2.00 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.83 | 52 Week High | $5.84 | |||
| Open | $128.67 | 52 Week Low | $5.49 | |||
| Day High | $134.75 | P/E | N/A | |||
| Day Low | $127.62 | EPS | $0.00 | |||
| Volume | 1,931,979 | |||||
